BioPharmSignal logoBioPharmSignal

Biotech News

Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026

Atea (AVIR)AteaEarnings

BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live

Open original release

Related news

AVIRAtea2026-02-26 12:00 EST

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026

AVIRAtea2026-05-12 20:06 EST

Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

ENTAEnanta Pharmaceuticals2026-02-09 21:01 EST

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025

ENTAEnanta Pharmaceuticals2025-11-17 21:01 EST

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025

SPROSpero Therapeutics2026-05-05 16:05 EST

Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

SPROSpero Therapeutics2025-05-05 08:00 EST

Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025

ABUSArbutus2026-05-13 11:30 EST

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

ANTXAN2 Therapeutics2026-05-11 20:01 EST

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

ASMBAssembly Biosciences2026-05-07 20:00 EST

Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

VIRIVirios Therapeutics2026-05-07 12:30 EST

Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

View all latest news

Atea

Atea Pharmaceuticals is an antiviral company focused on RNA polymerase inhibition and infectious-disease programs. Its story is centered on whether antiviral science can still create differentiated value after the pandemic cycle.

Recent company news

AVIRAtea2026-05-27 11:00 EST

Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026

AVIRAtea2026-05-13 11:00 EST

Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline

AVIRAtea2026-05-12 20:06 EST

Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

AVIRAtea2026-05-05 11:00 EST

Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026

AVIRAtea2026-03-05 21:05 EST

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Stock data

Close
4.82 USD
Market cap
341.72M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States